National Bank of Canada
RPTX

National Bank of Canada’s Repare Therapeutics RPTX Stock Holding History

National Bank of Canada’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-435
Closed -$570 – 3110
2024
Q4 		$570 Sell
435
-17
-4% -$51 ﹤0.01% 2707
2024
Q3 		$1.55K Sell
452
-1,173
-72% -$3.86K ﹤0.01% 2381
2024
Q2 		$5.38K Hold
1,625
– – ﹤0.01% 2245
2024
Q1 		$5.75K Hold
1,625
– – ﹤0.01% 2283
2023
Q4 		$11.8K Sell
1,625
-200
-11% -$1.12K ﹤0.01% 2126
2023
Q3 		$21.4K Hold
1,825
– – ﹤0.01% 2023
2023
Q2 		$19.3K Hold
1,825
– – ﹤0.01% 2019
2023
Q1 		$17.9K Hold
1,825
– – ﹤0.01% 1998
2022
Q4 		$26.8K Hold
1,825
– – ﹤0.01% 1936
2022
Q3 		$22K Sell
1,825
-100
-5% -$1.29K ﹤0.01% 1990
2022
Q2 		$27K Hold
1,925
– – ﹤0.01% 1979
2022
Q1 		$27K Sell
1,925
-100
-5% -$1.48K ﹤0.01% 2085
2021
Q4 		$43K Buy
+2,025
New +$47.7K ﹤0.01% 1922

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

National Bank of Canada's RPTX Position: Q1 2025 in Review

National Bank of Canada sold out of Repare Therapeutics (RPTX) in Q1 2025, closing a stake of 435 shares — an estimated $570 sold.

National Bank of Canada first reported a position in RPTX in Q4 2021 and held it in 13 quarters. The position peaked at $43K in Q4 2021. 50 funds tracked by Wall St. Rank hold RPTX as of Q1 2025.

  • National Bank of Canada reported no remaining Repare Therapeutics position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 435 Repare Therapeutics shares in Q1 2025, an estimated $570.
  • National Bank of Canada first reported a position in Repare Therapeutics in Q4 2021 and held it in 13 quarters.
  • National Bank of Canada's Repare Therapeutics position peaked at $43K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.